(Q36469806)

14 August 2017

title

The use of thalidomide in androgen-independent prostate cancer (English)

1 reference

14 August 2017

0 references

1 reference

Michael C Cox

1

1 reference

14 August 2017

William L Dahut

series ordinal

2

1 reference

14 August 2017

William D Figg

series ordinal

3

1 reference

14 August 2017

publication date

1 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

246-249

1 reference

14 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

An update on prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Tumor angiogenesis: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Angiogenesis in urological malignancy: prognostic indicator and therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Topography of neovascularity in human prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

A short history of thalidomide embryopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Thalidomide in the treatment of leprosy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.020

10.1016/J.UROLONC.2005.11.020

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference